Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 7/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SDHA | P31040 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537751 | 0.89 | CALML3 (0.45) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7537758 | 0.89 | CALML3 (0.45) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL16701320 | 0.85 | CALML3 (0.49) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL16701317 | 0.85 | CALML3 (0.49) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL4574440 | 0.84 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL1034941 | 0.82 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL1036062 | 0.82 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL13151038 | 0.82 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7538108 | 0.81 | MAOA (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7537986 | 0.80 | CALML3 (0.44) | CALML3CYP3A4CYP2D6MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
| US-6410728-B1 | BACTERICIDES; PSORIASIS; ANTIARTHRITIC AGENTS; TREATING TOXICITY DUE TO CHEMOTHERAPY; OBESITY; ANTIBIOTIC-RESISTANT STAPHYLOCOCCUS, MORAXELLA, ENTEROCOCCUS AND STREPTOCOCCUS; GRAMPOSITIVE BACTERIA | ABBOTT LABORATORIES | 2002-06-25 | — | — | US | disclosed |
| US-20020045625-A1 | OXAZOLIDINONE CHEMOTHERAPEUTIC AGENTS | ABBOTT LABORATORIES | 2002-04-18 | — | — | US | disclosed |
| WO-2002018353-A2 | OXAZOLIDINONE CHEMOTHERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6277868-B1 | BACTERICIDES; SKIN DISORDERS | ABBOTT LABORATORIES | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | TOP1, OXA1L, TK1 | CALML3 4325/4885CYP3A4 588/4885CYP2D6 101/4885 |
| US-20020045625-A1 | OXAZOLIDINONE CHEMOTHERAPEUTIC AGENTS | OXA1L, TK1, PDCD1 | CALML3 4272/4885CYP3A4 552/4885CYP2D6 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.